We’re developing CORA, a clinically validated, AI-powered system for CAD detection in primary care. Given Oregon Venture Fund's focus on transformative health tech, I believe AccuLine aligns well and could add distinct value to your portfolio. 

A few highlights: 

• Seasoned leadership: Executives and advisors with a proven track record in MedTech from Medtronic, J&J, Mayo Clinic, and the University of Michigan. 
• Massive market: $14B TAM | $10B SAM | $3B SOM. 
• Strong backing: $5.5M raised from Mayo Clinic, Maccabi Healthcare, eHealth Ventures, plus grants from Google and the IIA. 
• Fundraising: Currently raising a Series A, with 50% already secured. 
• Regulatory path: Preparing to launch a US multicenter clinical study toward FDA clearance.